- Boston Children's Hospital is seeking millions in unpaid royalties from Celgene (CELG), WSJ reports.
- In a lawsuit filed last summer, the hospital claims the company violated a 2002 contract when it ceased paying royalties on Revlimid and Pomalyst — the hospital apparently helped discover their cancer fighting abilities.
- The case is further complicated by the fact that the hospital sold most of its Revlimid rights to an unnamed third party for $130.5M.
- In any event, an unfavorable ruling would likely cost CELG millions, as "court filings [show] Children's [believes] it is owed $3M in unpaid royalties for the first quarter alone."
From other sites
at Nasdaq.com (Wed, 11:28AM)
at 4-traders.com (Mon, 1:45AM)
at Investopedia (Thu, 9:45AM)
at Zacks.com (Thu, 9:30AM)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs